DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions

Information source: Teva Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Tamsulosin (Drug); Tamsulosin (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Teva Pharmaceuticals USA

Official(s) and/or principal investigator(s):
Xueyu (Eric) Chen, M.D., Ph. D., FRCP (C), Principal Investigator, Affiliation: Pharma Medica Research, Inc.

Summary

The objective of this study is to evaluate the comparative bioavailability between tamsulosin hydrochloride 0. 4 mg capsules (Manufactured by Teva Pharmaceutical Industries Ltd.; distributed by Teva Pharmaceuticals USA) and Flomax® (tamsulosin hydrochloride)0. 4 mg capsules (Manufactured by Yamanouchi Pharmaceutical Co., Japan; distributed by Boehringer Ingelheim Pharmaceutical Inc. USA), after a single-dose in healthy subjects under fed conditions.

Clinical Details

Official title: A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Healthy, non-smoking male subjects, 18 years of age or older.

- BMI greater than or equal to 19 and less than or equal to 30.

- Negative for:

- HIV.

- Hepatitis B surface antigen and Hepatitis C antibody.

- Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine,

opiates, benzodiazepines and methadone).

- Urine cotinine test

- No significant diseases or clinically significant findings in a physical examination.

- No clinically significant abnormal laboratory values.

- No clinically significant findings in vital signs measurements and a 12-lead

electrocardiogram (ECG).

- Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between

60-90 mmgHg.

- Be informed of the nature of the study and given written consent prior to receiving

any study procedure. Exclusion Criteria:

- Known history or presence of any clinically significant medical condition, illness or

surgery within 4 weeks prior to drug administration.

- Known or suspected carcinoma.

- Known history or presence of:

- Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug

substances with similar activity.

- Alcoholism within the last 12 months.

- Drug dependence and/or substance abuse.

- Use of tobacco or nicotine-containing products within the last 6 months.

- Use of any prescription medication within 14 days prior to Period 1 dosing. Use of

any over the counter (OTC) medication within 7 days prior to Period 1 dosing.

- Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days

prior to Period 1 dosing.

- On a special diet within 4 weeks prior to drug administration (e. g. liquid, protein,

raw food diet).

- Participated in another clinical trial or received and investigational product within

30 days prior to drug administration.

- Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500

mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.

- Difficulty fasting or consuming the standard meals.

- Do not tolerate venipuncture.

- Unable to read or sign the ICF.

Locations and Contacts

Pharma Medica Research Inc., Toronto, Ontario M1R 5A3, Canada
Additional Information

Starting date: November 2004
Last updated: August 18, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017